Iterum Therapeutics plc
ITRM
$0.42
$0.000.77%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -94.20% | 0.88% | |||
| Gross Profit | 207.25% | -0.88% | |||
| SG&A Expenses | 55.14% | 50.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 46.88% | 49.03% | |||
| Operating Income | -39.83% | -49.03% | |||
| Income Before Tax | -37.16% | -33.51% | |||
| Income Tax Expenses | 123.73% | -1.67% | |||
| Earnings from Continuing Operations | -37.95% | -33.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -37.95% | -33.08% | |||
| EBIT | -39.83% | -49.03% | |||
| EBITDA | -42.45% | -54.06% | |||
| EPS Basic | -20.25% | -13.51% | |||
| Normalized Basic EPS | -19.62% | -13.88% | |||
| EPS Diluted | -20.25% | -13.51% | |||
| Normalized Diluted EPS | -19.62% | -13.88% | |||
| Average Basic Shares Outstanding | 14.69% | 17.25% | |||
| Average Diluted Shares Outstanding | 14.69% | 17.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||